التفاصيل البيبلوغرافية
| العنوان: |
Factors affecting adherence to a high-risk surveillance protocol among patients with Li-Fraumeni syndrome. |
| المؤلفون: |
Underkofler, Kaylee A., Thomas, Martha H., Taylor, Christina J., Mazur, Christa L., Erickson, Sarah H., Ring, Kari L. |
| المصدر: |
Hereditary Cancer in Clinical Practice; 8/11/2023, Vol. 21 Issue 1, p1-8, 8p |
| مصطلحات موضوعية: |
LI-Fraumeni syndrome, PATIENT compliance, EARLY detection of cancer |
| الشركة/الكيان: |
UNIVERSITY of Virginia |
| مستخلص: |
Background: High-risk surveillance for patients with Li-Fraumeni syndrome (LFS) has shown a stage shift and improved overall survival, but is demanding. Our objective was to evaluate surveillance adherence in a population of patients with LFS presenting for high-risk care. Methods: A retrospective analysis of surveillance adherence of adult patients with LFS at a single institution was performed. Adherence was defined by the duration from initial University of Virginia (UVA) LFS clinic visit to the time of first missed surveillance test. Two-sample t-tests and ANOVA tests were used to identify factors associated with duration of adherence. Results: A total of 42 patients were evaluated in the UVA LFS clinic between 2017 and 2021. Of these, 21 patients met inclusion criteria. At the time of review, 6 patients (29%) were up to date with high-risk surveillance recommendations. The mean duration of adherence was 17 months. Female sex was found to be associated with longer duration of adherence (mean 21 mo vs. 3.5 mo for males, p = 0.02). A personal history or active diagnosis of cancer was also associated with increased adherence (p = 0.02). However, neither age (p = 0.89), geography (p = 0.84), or known family history of LFS (p = 0.08) were associated with duration of adherence. Conclusion: Female sex as well as a personal history of cancer were associated with longer duration of adherence to recommended high-risk surveillance among patients with LFS. Identification of barriers to surveillance will be essential moving forward to increase adherence and promote early detection of cancer, thereby reducing the morbidity and mortality of LFS. [ABSTRACT FROM AUTHOR] |
|
Copyright of Hereditary Cancer in Clinical Practice is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder